Key Points
- Adlai Nortye director Ping Ji sold 10,000 shares at an average price of $15.99, generating $159,900. Following the transaction, Ji owned 121,453 shares, a 7.61% reduction in holdings.
- ANL shares opened at $15.76 and have traded between $0.88 and $17.25 over the past year. Institutional investors own approximately 35.21% of the company, with several hedge funds recently establishing positions.
- Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $29.50, well above the current share price.
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) Director Ping Ji sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total value of $159,900.00. Following the transaction, the director owned 121,453 shares of the company's stock, valued at approximately $1,942,033.47. This trade represents a 7.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Ping Ji also recently made the following trade(s):
- On Tuesday, September 29th, Ping Ji sold 214 shares of Adlai Nortye stock. The stock was sold at an average price of $15.77, for a total transaction of $3,374.78.
- On Tuesday, September 22nd, Ping Ji sold 5,000 shares of Adlai Nortye stock. The stock was sold at an average price of $16.63, for a total transaction of $83,150.00.
Adlai Nortye Stock Performance
Shares of ANL stock opened at $15.76 on Friday. Adlai Nortye Ltd. Sponsored ADR has a one year low of $0.88 and a one year high of $17.25. The company's fifty day moving average price is $14.28 and its 200-day moving average price is $12.25.
Hedge Funds Weigh In On Adlai Nortye
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANL. Braidwell LP purchased a new stake in shares of Adlai Nortye during the 2nd quarter worth approximately $9,145,000. Boone Capital Management LLC bought a new position in shares of Adlai Nortye during the 2nd quarter valued at approximately $2,971,000. Seven Fleet Capital Management LP purchased a new position in shares of Adlai Nortye in the second quarter valued at $1,302,000. Affinity Asset Advisors LLC purchased a new position in shares of Adlai Nortye in the first quarter valued at $1,140,000. Finally, ADAR1 Capital Management LLC bought a new stake in Adlai Nortye in the first quarter worth $816,000. 35.21% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on ANL shares. Cantor Fitzgerald began coverage on Adlai Nortye in a research report on Monday, June 22nd. They issued an "overweight" rating on the stock. Loop Capital set a $49.00 target price on Adlai Nortye in a research report on Tuesday, September 8th. Wall Street Zen downgraded Adlai Nortye from a "buy" rating to a "hold" rating in a research note on Saturday, September 12th. Jefferies Financial Group started coverage on Adlai Nortye in a report on Thursday, September 10th. They issued a "buy" rating and a $31.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Adlai Nortye in a research note on Tuesday, September 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adlai Nortye presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.50.
View Our Latest Stock Analysis on ANL
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company's research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.
Adlai Nortye's lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
